Drug Type Small molecule drug |
Synonyms Carbenoxolone, Carbenoxolone sodium (JAN/USAN), Vampex + [6] |
Target- |
Mechanism Gap junctions blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date GB (01 Jan 1959), |
RegulationOrphan Drug (US) |
Molecular FormulaC34H50Na2O7 |
InChIKeyOUNBBVKBERWKFE-SBBGFIFASA-N |
CAS Registry7421-40-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01899 | Carbenoxolone Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Peptic Ulcer | GB | - | 01 Jan 1959 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psoriasis | Phase 2 | GB | - | |
Huntington Disease | Preclinical | US | 30 Jan 2022 | |
Parkinson Disease | Preclinical | US | 30 Jan 2022 |
Not Applicable | Ocular Hypertension 11 beta-hydroxysteroid dehydrogenase type 1 | 20 | Carbenoxolone (CBX) | zeghmgvrof(uofqnrvqul) = atrwcdueqg tqsyconkrw (rzdpemgykt ) | - | 01 Dec 2002 |